Changes in the structure of primary care delivery, and differences in content of telemedicine visits vs. office-based visits were observed in the USA during the COVID-19 pandemic.

ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.

Prof. De Boer discusses a recent paper in JAMA Cardiol on cardiac abnormalities detected by cardiovascular MRI in 100 patients who had proven COVID-19 around 2 months ago.

Cardiovascular MRI revealed cardiac involvement in 78% of patients and ongoing myocardial inflammation in 60% of patients in an unselected cohort of 100 patients who recently recovered from COVID-19.

A survey conducted by the ESC among cardiologists and CV nurses revealed that 78.8% of responders perceived a decrease in STEMI admissions since the beginning of the COVID-19 outbreak.

Out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak was substantially increased in the Lombardia region in Italy compared to the same period in 2019. Baldi briefly presents the details and outcomes of a study.

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and (ARBs in patients with COVID-19, which all three showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19

This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.

This comment article describes characteristics of coagulopathy in patients with COVID-19 and discusses recommendations for the therapeutic management of COVID-19-associated coagulopathy.

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.